13F Holdings
中文EN

QTTB Q32 Bio Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1661998 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY176.6%
TTM EPS YoY210.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE24.0%
ROA18.2%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets3.2%
Debt / equity0.00x
Current ratio56.34x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-0.62x
Accruals ratio29.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$53.74M$0-$6.65M$3.21M$33.97M
R&D expense$19.16M$48.14M$31.73M$98.35M$93.08M
SG&A expense$17.68M$17.96M$9.88M$38.14M$36.84M
Operating income$16.90M-$66.10M-$48.26M-$133.28M-$95.95M
Interest expense——$1.50M——
Pretax income$29.82M-$46.09M-$53.42M$1.20M-$95.76M
Income tax$0$21,000$318,000$715,000$0
Net income$29.82M-$47.73M-$53.74M-$5.00M-$95.76M
EBITDA$17.29M-$65.61M-$47.76M-$131.99M-$87.60M
EPS (basic)2.42-5.12-153.96-0.09-1.73
EPS (diluted)2.42-6.58-153.96-0.09-1.73
Weighted avg. shares (diluted)12.31M9.66M349,06057.40M55.28M
Banking
Net interest income$1.05M$2.83M$693,000——
Balance sheet
Cash & equivalents$48.30M$78.61M$31.26M$49.54M$108.38M
Short-term investments—$0$0$141.04M$47.49M
Current assets$55.05M$81.88M$28.72M$181.01M$191.91M
PP&E, net$979,000$1.37M$1.78M$1.08M$2.25M
Total assets$61.78M$92.33M$47.06M$228.47M$211.72M
Current liabilities$11.35M$16.46M$14.11M$22.58M$17.23M
Total liabilities$19.76M$86.66M$118.53M$50.49M$42.07M
Shareholders' equity$42.01M$5.67M-$182.92M-$130.71M$169.65M
Shares outstanding12.86M12.20M359,56957.48M57.15M
Cash flow statement
Operating cash flow-$33.54M-$67.72M-$18.68M-$113.66M-$109.75M
Capital expenditure$0$75,000$5,000$1.28M$2.40M
Free cash flow-$33.54M-$67.79M-$18.68M-$114.95M-$112.15M
Investing cash flow$7.00M$19.93M-$5,000$36.72M-$50.79M
Financing cash flow-$3.12M$95.14M$406,000$596,000$52.17M
Depreciation & amortization$391,000$487,000$499,000$1.29M$8.35M
Stock-based compensation$5.25M$4.39M$1.43M$13.05M$17.25M

Free plan shows the latest 5 periods; Pro shows all 9 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.